Abstract
Objective a) to determine the factors associated with the presence of peripheral manifestations in patients with spondyloarthritis (SpA) from the ASAS-COMOSPA study, b) to evaluate the impact of these symptoms on treatment and Patient Reported Outcomes (PROs).
Methods All patients from the ASAS-COMOSPA study were included. All patients had a SpA diagnosis according to the rheumatologist. Patients and disease characteristics associated with the presence of these peripheral manifestations (peripheral arthritis, peripheral enthesitis or dactylitis) were explored by univariate and multivariate logistic regression. Patients who reported peripheral manifestations were divided into three categories: current, past history and no history. The impact of peripheral involvement on PROs was evaluated through the use of one-factor ANOVA.
Results Out of the 3984 patients included in ASAS-COMOSPA, 2562 (64.3%) reported at least one peripheral manifestation, with a prevalence of 51.5%, 37.8% and 15.6% for peripheral arthritis, peripheral enthesitis and dactylitis, respectively. South American patients, history of uveitis, current or past history of psoriasis, and the absence of HLAB27 were associated with higher prevalence of peripheral manifestations. Patients with peripheral involvement showed greater use of drugs, and those with “current” peripheral manifestations showed higher levels in all PROs, in contrast to those with past or no history.
Conclusion Peripheral manifestations appear in 64% of patients with SpA. Psoriasis and the absence of HLAB27 are associated with the development of peripheral symptoms. The presence of any peripheral symptom at the time of the visit was associated with higher scores in all PROs.
In this issue
